Interstitial lung disease associated with FOLFOX chemotherapy

Area of Science:

• Oncology
• Pulmonology
• Gastroenterology

Background:

• FOLFOX (folinic acid, fluorouracil, and oxaliplatin) is a standard chemotherapy for advanced gastrointestinal cancers.
• Oxaliplatin-induced toxicities are typically gastrointestinal, hematological, and neurosensory.
• Pulmonary toxicity associated with FOLFOX is rarely reported and poorly understood.

Observation:

• A patient with metastatic advanced gastric cancer received FOLFOX chemotherapy.
• The patient developed interstitial lung disease.
• The patient experienced progressive respiratory failure and ultimately expired.

Findings:

• This case presents a fatal outcome of interstitial lung disease potentially induced by FOLFOX chemotherapy.
• The severe pulmonary toxicity led to acute respiratory failure.

Implications:

• Interstitial lung disease should be considered in the differential diagnosis of new lung lesions in patients undergoing FOLFOX chemotherapy.
• Further investigation into the association between FOLFOX and severe pulmonary toxicity, including acute respiratory failure, is warranted.